
Eli Lilly hits the gas on tirzepatide in obesity, nabs rolling submission for potential blockbuster indication
In the already buzzy obesity drug market, Eli Lilly is the latest newsmaker, nabbing a fast-track designation and rolling review from the FDA on Thursday.
While Lilly’s tirzepatide study in obesity initially read out positive results in April, it’s initiating an FDA filing as it awaits results from a second Phase III study.
Lilly’s initial SURMOUNT-1 study showed up to 22% weight loss, and as it noted to Endpoints News recently, those results are beginning to approach levels of bariatric surgery which averages 25-30% of body weight loss.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.